Three Year Metrics (2008 – 2010): Phase II – IV

Clinical Research Atlanta maintains performance metrics on a quarterly basis. In addition to metrics by therapeutic area, CRA is proud of some additional performance measures outlined below.

  • Regulatory and Contract Turnaround:  Less than one week
  • First Subject In from Contract Date:  1-2 days
  • eCRF data entry:  within 24 hours of patient visit and same day for queries generated by monitor visit.

 

RESPIRATORY

(Includes Seasonal and Perennial Allergic Rhinitis, Asthma, COPD and Cold/Flu)

  • Number of Trials: 35
  • Screened Patients that Randomize: 74%
  • Contracted Enrollment that Complete Trial: 104%
  • Randomized Patients that Early Terminate: 8%
  • Randomized Patients that Complete Trial: 86%
  • Enrollment Rate: 121%

 

GASTROENTEROLOGY

(including GERD, Chronic Constipation and IBS)

  • Number of Trials: 29
  • Screened Patients that Randomize: 78%
  • Contracted Enrollment that Complete Trial: 75%
  • Randomized Patients that Early Terminate: 51%
  • Randomized Patients that Complete Trial: 61%
  • Enrollment Rate: 123%

 

ORTHOPAEDIC

{including Osteoarthritis of Knee and Tendonitis)

  • Number of Trials: 4
  • Screened Patients that Randomize: 71%
  • Contracted Enrollment that Complete Trial: 112%
  • Randomized Patients that Early Terminate: 4%
  • Randomized Patients that Complete Trial: 96%
  • Enrollment Rate: 117%

 

METABOLIC

(including Obesity, Gout and Type II Diabetes)

  • Number of Trials: 6
  • Screened Patients that Randomize: 70%
  • Contracted Enrollment that Complete Trial: 52%
  • Randomized Patients that Early Terminate: 29%
  • Randomized Patients that Complete Trial: 47%
  • Enrollment Rate: 109%

 

VACCINE

  • Number of Trials: 11
  • Screened Patients that Randomize: 96%
  • Contracted Enrollment that Complete Trial: 105%
  • Randomized Patients that Early Terminate: 2%
  • Randomized Patients that Complete Trial: 98%
  • Enrollment Rate: 107%

 

PEDIATRIC TRIALS

(including Seasonal and Perennial Allergic Rhinitis and Normal Healthy)

  • Number of Trials: 6
  • Screened Patients that Randomize: 74%
  • Contracted Enrollment that Complete Trial: 89%
  • Randomized Patients that Early Terminate: 23%
  • Randomized Patients that Complete Trial: 77%
  • Enrollment Rate: 115%

 

OVERACTIVE BLADDER

  • Number of Trials: 1
  • Screened Patients that Randomize: 43%
  • Contracted Enrollment that Complete Trial: 225%
  • Randomized Patients that Early Terminate: 10%
  • Randomized Patients that Complete Trial: 90%
  • Enrollment Rate: 250%

 

TINEA PEDIS

  • Number of Trials: 1
  • Screened Patients that Randomize: 75%
  • Contracted Enrollment that Complete Trial: 30%
  • Randomized Patients that Early Terminate: 0%
  • Randomized Patients that Complete Trial: 67%
  • Enrollment Rate: 45%

 

HYPERTENSION

  • Number of Trials: 4
  • Screened Patients that Randomize: 46%
  • Contracted Enrollment that Complete Trial: 104%
  • Randomized Patients that Early Terminate: 3%
  • Randomized Patients that Complete Trial: 107%
  • Enrollment Rate: 107%

 

MIGRAINE

  • Number of Trials: 2
  • Screened Patients that Randomize: 37%
  • Contracted Enrollment that Complete Trial: 53%
  • Randomized Patients that Early Terminate: 36%
  • Randomized Patients that Complete Trial: 71%
  • Enrollment Rate: 74%

 

NORMAL HEALTHY

  • Number of Trials: 2
  • Screened Patients that Randomize: 100%
  • Contracted Enrollment that Complete Trial: 145%
  • Randomized Patients that Early Terminate: 18%
  • Randomized Patients that Complete Trial: 82%
  • Enrollment Rate: 178%